These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 3999371)

  • 21. [Cholesterol: how and when to treat it?].
    Masana Marín L
    Med Clin (Barc); 1985 Oct; 85(10):423-5. PubMed ID: 4079497
    [No Abstract]   [Full Text] [Related]  

  • 22. [High cholesterol levels are discriminated by new therapeutic recommendations].
    Olsson AG
    Lakartidningen; 2000 Apr; 97(16):1995-6. PubMed ID: 10826361
    [No Abstract]   [Full Text] [Related]  

  • 23. [CARE[ Cholesterol and Recurrent Events Trial]].
    Oida K
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():427-32. PubMed ID: 11347108
    [No Abstract]   [Full Text] [Related]  

  • 24. Dyslipidemia and coronary heart disease: management issues from Indian perspective.
    Gambhir DS; Gambhir JK; Sudha R
    Indian Heart J; 2000; 52(5):515-6, 617. PubMed ID: 11256772
    [No Abstract]   [Full Text] [Related]  

  • 25. A secondary prevention lipid clinic reaches low-density lipoprotein cholesterol goals more often than usual cardiology care with coronary heart disease.
    Birtcher KK; Greisinger AJ; Brehm BJ; Wehmanen OA; Furman LM; Salinas CC; Mirzai-Tehrane M; Nayak A; Rashid H; Mortazavi A
    J Clin Lipidol; 2010; 4(1):46-52. PubMed ID: 21122626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of serum lipid level change on 10-year coronary heart risk distribution estimated by means of seven different coronary risk scores during one-year treatment.
    Kojić NE; Derić M; Dejanović J
    Med Pregl; 2014; 67(7-8):208-15. PubMed ID: 25151760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Achieving National Cholesterol Education Program goals for low-density lipoprotein cholesterol in cardiac patients: importance of diet, exercise, weight control, and drug therapy.
    Allison TG; Squires RW; Johnson BD; Gau GT
    Mayo Clin Proc; 1999 May; 74(5):466-73. PubMed ID: 10319076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Primary prevention of coronary disease by modification of the lipids].
    Augustin J
    Dtsch Med Wochenschr; 1984 Jun; 109(24):965-7. PubMed ID: 6376043
    [No Abstract]   [Full Text] [Related]  

  • 29. Prevention of coronary heart disease in primary medical care in Poland: results from the LIPIDOGRAM study.
    Tomasik T; Jozwiak J; Windak A; Rygiel K; Mastej M; Smithson WH; Mathers N; Tomaszewski M; Kaess BM; Tykarski A; Konduracka E; Grzeszczak W; Lukas W
    Eur J Cardiovasc Prev Rehabil; 2011 Apr; 18(2):287-96. PubMed ID: 21450675
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Introduction to risk assessment and serum risk markers for the prevention of coronary heart disease and other potential conditions that impact men's health, part I: what do I tell my patients?
    Moyad MA
    Urol Clin North Am; 2004 May; 31(2):195-8. PubMed ID: 15123398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
    Frick MH; Elo O; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P; Manninen V
    N Engl J Med; 1987 Nov; 317(20):1237-45. PubMed ID: 3313041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Relation between the lipid picture and coronary artery disease documented angiographically].
    Binaghi F; Valle E; Manconi E; Martelli V; Pitzus F
    Minerva Cardioangiol; 1985 Sep; 33(9):547-52. PubMed ID: 4088482
    [No Abstract]   [Full Text] [Related]  

  • 33. Preventive strategies for reducing coronary heart disease-related morbidity and mortality in patients with multiple risk factors.
    Brown WV
    J Am Osteopath Assoc; 2001 Sep; 101(9 Suppl):S6-11. PubMed ID: 11575043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical inquiries. What is the best strategy for monitoring the lipid-lowering effects of medical therapy used for the primary prevention of coronary artery disease (CAD)?
    Sherrod JP; Krist A
    J Fam Pract; 2001 Nov; 50(11):928. PubMed ID: 11711006
    [No Abstract]   [Full Text] [Related]  

  • 35. Cholesterol and coronary heart disease: predicting risks in men by changes in levels and ratios.
    Kinosian B; Glick H; Preiss L; Puder KL
    J Investig Med; 1995 Oct; 43(5):443-50. PubMed ID: 8528755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
    Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipid Research Clinics Coronary Primary Prevention Trial results.
    Virkkunen M
    JAMA; 1985 Feb; 253(5):635-6. PubMed ID: 3968799
    [No Abstract]   [Full Text] [Related]  

  • 38. Primary prevention of coronary artery disease.
    Domanski MJ
    N Engl J Med; 2007 Oct; 357(15):1543-5. PubMed ID: 17928603
    [No Abstract]   [Full Text] [Related]  

  • 39. [Primary and secondary prevention of coronary disease by statins].
    Ferrières J
    Ann Cardiol Angeiol (Paris); 1999 Feb; 48(2):128-36. PubMed ID: 12555337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Lipid Research Clinics Coronary Primary Prevention Trial.
    L'Abbé KA; Detsky AS; Logan AG
    JAMA; 1985 Jun; 253(21):3091. PubMed ID: 3889392
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.